{
  "title": "Paper_146",
  "abstract": "pmc BMC Health Serv Res BMC Health Serv Res 34 bmchsr BMC Health Services Research 1472-6963 BMC PMC12490126 PMC12490126.1 12490126 12490126 10.1186/s12913-025-13540-9 13540 1 Research Barriers and solutions in cross-sector care for metastatic prostate cancer patients in Germany: a qualitative study on radioligand therapy Schenzle Carolin carolin-schenzle@t-online.de https://ror.org/02kkvpp62 grid.6936.a 0000 0001 2322 2966 Department Health and Sport Sciences, School of Medicine and Health, Technical University of Munich, 2 10 2025 2025 25 478160 1281 3 1 2024 19 9 2025 02 10 2025 03 10 2025 03 10 2025 © The Author(s) 2025 2025 https://creativecommons.org/licenses/by/4.0/ Open Access http://creativecommons.org/licenses/by/4.0/ Background In December 2022, Pluvicto ® 177 177 Methods Eighteen physicians involved in the care of metastatic prostate cancer in the outpatient and inpatient settings from different regions of Germany participated in this semi-structured, qualitative expert interview study. Qualitative content analysis with inductive category formation was used to analyze the data. Results Four major thematic categories were identified regarding barriers to care: (a) research-practice gap, (b) challenges to interprofessional collaboration, (c) resource constraints, and (d) unwarranted variation in care. Expert suggestions for resolving these barriers were grouped into the corresponding major thematic categories: (a) knowledge management, (b) integration of care, (c) capacity planning, and (d) facilitation of access. Conclusions The delivery of 177 Supplementary Information The online version contains supplementary material available at 10.1186/s12913-025-13540-9. Keywords Radioligand therapy Prostate cancer [177Lu]Lu-PSMA [68 Ga]Ga-PSMA PET/CT imaging PSMA pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes issue-copyright-statement © BioMed Central Ltd., part of Springer Nature 2025 Background Radioligand therapy (RLT) with Lutetium-177 ( 177 1 2 177 3 4 4 ® 5 9 ® 8 10 12 13 177 8 12 14 ® 12 15 16 177 17 Methods This study intended to offer an informative foundation for 177 What current barriers to cross-sector care for mPC with 177 What solutions to the identified barriers do physicians propose based on their experiences in daily practice to improve patient care? Semi-structured interviews with experts in the care of patients with mPC served as the data collection method. The development of the interview guide (Additional file 1) followed the process of operationalization by Kaiser [ 18 19 20 21 1 22 23 Evaluation unit: the entire text material (18 transcripts) Context unit: the whole interview Coding unit: clear semantic elements Table 1 Professional characteristics of the participants Interview Sector Specialist group Federal state ASV a 1 Outpatient Internal medicine and hematology and oncology Hesse Yes 2 Outpatient Urology + med. TT Saxony-Anhalt No 3 Outpatient Nuclear medicine Hamburg Yes 4 Outpatient Urology + med. TT Schleswig-Holstein No 5 Outpatient Urology + med. TT Hamburg Yes 6 Inpatient Urology + med. TT Hamburg In process 7 Outpatient Nuclear medicine Bavaria Yes 8 Outpatient Urology Bavaria No 9 Outpatient Nuclear medicine Saxony No 10 Outpatient Urology + med. TT Rhineland Palatinate No 11 Inpatient Nuclear medicine Baden-Wurttemberg Yes 12 Inpatient Nuclear medicine Mecklenburg-West Pomerania No 13 Inpatient Nuclear medicine North Rhine-Westphalia Yes 14 Inpatient Urology + med. TT Saxony-Anhalt Yes 15 Inpatient Nuclear medicine North Rhine Westphalia No 16 Inpatient Nuclear medicine Lower Saxony In process 17 Inpatient + outpatient Nuclear medicine Hesse Yes 18 Inpatient Urology + med. TT Bavaria No ASV Med. TT a Selection criteria can be seen in the Additional file 2. A minimum of two appearances in different interviews was set as the threshold for categories relating to barriers. Results The analysis of the interview material based on the first research question yielded 23 categories. These were combined into main categories and grouped into four major thematic categories: (a) research-practice gap, (b) challenges to interprofessional collaboration, (c) resource constraints, and (d) unwarranted variation in care. For the second research question, the same procedure resulted in 30 categories, which were summarized and grouped into four major thematic categories: (a) knowledge management, (b) integration of care, (c) capacity planning, and (d) facilitation of access. Figure 1 23 Fig. 1 Category system of barriers and solutions in the care of radioligand therapy Research-practice gap Among implementation barriers related to the external context 24 25 26 27 ® 28 ® ® Implementation barriers related to the physician 177 Challenges to interprofessional collaboration Among barriers to the implementation of health care teams, breaks in communication Resource constraints Regarding infrastructural challenges 68 operational challenges ® Unwarranted variation in care This major thematic category captures deviations in patient care that cannot be attributed to variations among patients themselves. The main category of access varies with physician access varies with health insurance Access varies with geography Knowledge management This major thematic category summarizes ideas for bridging the identified gap between research and practice. One component, knowledge dissemination, includes educating physicians via congresses or apps, timely guideline updates, interprofessional networking events, and training regulatory staff on relevant 177Lu-PSMA-RLT regulations. Knowledge production involves expanding studies and establishing a registry to collect real-world evidence. Finally, knowledge application highlights physicians’ desire for greater professional autonomy in making medical decisions regarding 177Lu-PSMA-RLT or PET/CT. Integration of care This major thematic category contains ideas on different ways to integrate providers and improve collaboration. Suggestions for functional integration organizational integration Normative integration Professional integration Capacity planning To address resource scarcity, one approach was to improve resource capacity utilization esource allocation ® Facilitation of access Easing access to 177 facilitate service utilization improve service availability Discussion This study is the first qualitative investigation of 177 177 68 177 29 18 68 18 30 ® 25 ® 31 177 177 177 15 177 177 2 32 33 2 34 35 38 38 35 36 39 43 38 38 37 44 45 39 41 46 51 38 52 53 56 38 57 58 59 59 52 60 61 62 52 15 63 64 177 65 65 67 68 68 70 61 177 71 72 177 Conclusions This qualitative study highlights the hurdles hindering the delivery of 177 Abbreviations  Abbreviation German English 18 Fluorine-18 68 Gallium-68 177 Lutetium-177 ASV ambulante spezialfachärztliche Versorgung Outpatient specialist care CT computed tomography EBM Einheitlicher Bewertungsmaßstab Uniform value scale mCRPC Metastatic castration-resistant prostate cancer MD Medizinischer Dienst Medical service mPC Metastatic prostate cancer MVZ Medizinisches Versorgungszentrum Medical care center NUB Neue Untersuchungs- und Behandlungsmethoden New examination and treatment methods PC Prostate cancer PET/CT Positron emission tomography/computed tomography PSMA Prostate-specific membrane antigen RLT Radioligand therapy SPECT/CT Single photon emission computed tomography/computed tomography Electronic supplementary material Below is the link to the electronic supplementary material.  Supplementary Material 1  Supplementary Material 2  Supplementary Material 3  Supplementary Material 4  Supplementary Material 5 Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Acknowledgements I would like to thank my supervisors Philip Bammert and Prof. Dr. Leonie Sundmacher at the Technical University of Munich and Magnus Fischer at Novartis Radiopharmaceuticals GmbH for their support with this thesis. Furthermore, I want to thank all the physicians who took their time to participate in this study. Author contributions The author confirms sole responsibility for the following: study conception and design, data collection, analysis and interpretation of results, and manuscript preparation. Funding This work was supported by Novartis Radiopharmaceuticals GmbH. The funding body had no influence on the data interpretation, analysis, or the manuscript. Data availability Interview transcripts generated and analyzed during the current study are not publicly available due to the protection of the participant’s privacy. Additional, fully anonymized, and aggregated data is however available from the author upon reasonable request. Declarations Ethics approval and consent to participate The Ethics Committee of the Technical University of Munich waived the need for ethics approval for this interview study. All participants provided written informed consent prior to their participation in the study. In the case of employed physicians, additional written consent was obtained from their institution. The study was conducted in accordance with the principles of the Declaration of Helsinki. Consent for publication Not applicable. Authors’ information This thesis was written as part of a master’s thesis for the M.Sc. Health Science degree at the Technical University of Munich. The work was supervised by the Chair of Health Economics at the Technical University of Munich and Novartis Radiopharmaceuticals GmbH. Competing interests The authors declare no competing interests. References 1. Baum R Radiomolecular precision oncology: a comprehensive treatment approach with high potential Eur Pharm Rev 2022 27 1 28 31 Baum R. Radiomolecular precision oncology: a comprehensive treatment approach with high potential. Eur Pharm Rev. 2022, Feb;27(1):28–31. 2. Lenzen-Schulte M. Radioligandentherapie: Die Ultima Ratio beim Prostatakrebs. Deutsches Ärzteblatt [Internet]. 2017, Nov, 3;44(114). Available from: https://www.aerzteblatt.de/archiv/194228/Radioligandentherapie-Die-Ultima-Ratio-beim-Prostatakrebs 3. Pluvicto EMA. EPAR - Product information [Internet]. 2023 Feb. Available from: https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf 4. Sartor O de Bono J Chi KN Fizazi K Herrmann K Rahbar K Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer N Engl J Med 2021 385 12 1091 103 10.1056/NEJMoa2107322 34161051 PMC8446332 Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021, Sep, 16;385(12):1091–103. 34161051 10.1056/NEJMoa2107322 PMC8446332 5. D. Metastasierter Prostatakrebs: Neues Medikament (Pluvicto®) in Europa zugelassen - [Internet]. 2022. Available from: https://www.krebsinformationsdienst.de/aktuelles/2022/news059-metastasierter-prostatakrebs-zulassung-pluvicto-lutetium-177-psma-617-europa.php 6. Pluvicto EMA. EPAR - Medicine overview [Internet]. 2022. Available from: https://www.ema.europa.eu/en/documents/overview/pluvicto-epar-medicine-overview_en.pdf 7. Hennrich U Eder M [177Lu]Lu-PSMA-617(PluvictoTM): The first FDA-approved radiotherapeutical for treatment of prostate cancer Pharmaceuticals (basel) 2022 15 10 1292 10.3390/ph15101292 36297404 PMC9608311 Hennrich U, Eder M. [177Lu]Lu-PSMA-617(PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer. Pharmaceuticals (Basel). 2022, Oct, 20;15(10):1292. 36297404 10.3390/ph15101292 PMC9608311 8. Jang A Kendi AT Sartor O Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials Ther Adv Med Oncol 2023 15 17588359231157632 10.1177/17588359231157632 36895851 PMC9989419 Jang A, Kendi AT, Sartor O. Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials. Ther Adv Med Oncol. 2023, Mar, 4;15:17588359231157632. 36895851 10.1177/17588359231157632 PMC9989419 9. Novartis. Novartis. Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer. 2022. Available from: https://www.novartis.com/news/media-releases/novartis-pluvictotm-approved-fda-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer 10. Novartis Pharmaceuticals. PSMAfore: a phase III, open-label, multi-center, randomized study comparing 177Lu-PSMA-617 vs. A change of androgen receptor-directed therapy in the treatment of taxane Naïve men with progressive metastatic castrate resistant prostate cancer [Internet]. clinicaltrials.govclinicaltrials.gov; Report No.: NCT04689828 https://clinicaltrials.gov/study/NCT04689828 11. Novartis Pharmaceuticals. An open-label, randomized, phase III study comparing 177Lu-PSMA-617 in combination with standard of care, versus standard of care alone, in adult male patients with metastatic hormone sensitive prostate cancer (mHSPC). [Internet]. clinicaltrials.gov; 2023, Jul. Available from: https://clinicaltrials.gov/study/NCT04720157 NCT04720157 12. The Health Policy Partnership. Health system readiness for radioligand therapy in the US: situation analysis report. 2021, Nov.30. London. 13. Merkel C Whicher CH Bomanji J Herrmann K Ćwikła J Jervis N Realising the potential of radioligand therapy: policy solutions for the barriers to implementation across Europe Eur J Nucl Med Mol Imaging 2020 47 6 1335 39 10.1007/s00259-020-04745-7 32170345 PMC7188707 Merkel C, Whicher CH, Bomanji J, Herrmann K, Ćwikła J, Jervis N, et al. Realising the potential of radioligand therapy: policy solutions for the barriers to implementation across Europe. Eur J Nucl Med Mol Imaging. 2020;47(6):1335–39. 32170345 10.1007/s00259-020-04745-7 PMC7188707 14. Berger-Thürmel K Westphalen CB von B-BM Patient access - Zugang zu Innovationen in der Onkologie Dtsch Med WochenschR 2023 148 6 306 12 10.1055/a-1929-6599 36878229 Berger-Thürmel K, Westphalen CB, von B-BM. Patient access - Zugang zu Innovationen in der Onkologie. Dtsch Med Wochenschr. 2023, Mar;148(6):306–12. 36878229 10.1055/a-1929-6599 15. The Health Policy Partnership. Radioligand therapy: releasing the potential of targeted cancer care [Internet]. 2020 Jan. Available from: https://www.healthpolicypartnership.com/app/uploads/Radioligand-therapy-realising-the-potential-of-targeted-cancer-care.pdf 16. Hehakaya C Moors EHM Verkooijen HM Grobbee DE Verburg FA Lam MGEH 177Lu-PSMA for advanced prostate cancer: are we ready to play big? Eur J Nucl Med Mol Imaging 2021 48 8 2325 28 10.1007/s00259-020-05102-4 33161440 Hehakaya C, Moors EHM, Verkooijen HM, Grobbee DE, Verburg FA, Lam MGEH. 177Lu-PSMA for advanced prostate cancer: are we ready to play big? Eur J Nucl Med Mol Imaging. 2021, Jul, 1;48(8):2325–28. 33161440 10.1007/s00259-020-05102-4 17. Zippel C Giesel FL Kratochwil C Eiber M Rahbar K Albers P PSMA-Radioligandentherapie könnte Nuklearmedizin vor infrastrukturelle Herausforderungen stellen: Ergebnisse einer Basiskalkulation zur Kapazitätsplanung nuklearmedizinischer Betten im deutschen Krankenhaussektor Nuklearmedizin 2021 60 3 216 23 10.1055/a-1351-0030 33530110 Zippel C, Giesel FL, Kratochwil C, Eiber M, Rahbar K, Albers P, et al. PSMA-Radioligandentherapie könnte Nuklearmedizin vor infrastrukturelle Herausforderungen stellen: Ergebnisse einer Basiskalkulation zur Kapazitätsplanung nuklearmedizinischer Betten im deutschen Krankenhaussektor. Nuklearmedizin. 2021, Jun;60(3):216–23. 33530110 10.1055/a-1351-0030 18. Kaiser R. Qualitative Experteninterviews: Konzeptionelle Grundlagen und praktische Durchführung [Internet]. Wiesbaden: Springer Fachmedien; 2014. Available from: https://link.springer.com/10.1007/978-3-658-02479-6 19. BMC. Intersektorale Versorgung ohne Therapiebrüche Forderungen der Arbeitsgruppe Intersektorale Versorgung im BMC [Internet]. 2019 Apr. Available from: https://www.bmcev.de/wp-content/uploads/Forderungskatalog_AG-Intersektorale-Versorgung-1.pdf 20. Korzilius H Sektorübergreifende Versorgung: Ambulante Angebote ausbauen Deutsches Ärzteblatt 2017 114 24 1162 63 Korzilius H. Sektorübergreifende Versorgung: Ambulante Angebote ausbauen. Deutsches Ärzteblatt. 2017, Jun, 16;114(24):1162–63. 21. Onwuegbuzie AJ Leech NL A call for qualitative power analyses Qual Quant 2007 41 1 105 21 10.1007/s11135-005-1098-1 Onwuegbuzie AJ, Leech NL. A call for qualitative power analyses. Qual Quant. 2007, Feb, 1;41(1):105–21. 22. Mayring P Qualitative Inhaltsanalyse: Grundlagen und Techniken. 12., überarbeitete Auflage 2015 Weinheim Basel Beltz 152 p Mayring P. Qualitative Inhaltsanalyse: Grundlagen und Techniken. 12., überarbeitete Auflage. Weinheim Basel: Beltz; 2015. p. 152. 23. Mayring P Qualitative content analysis: a step-by-step guide 2022 Thousand Oaks SAGE Publications Mayring P. Qualitative content analysis: a step-by-step guide. Thousand Oaks: SAGE Publications; 2022. 24. Leitlinienprogramm Onkologie: Prostatakarzinom [Internet]. Available from: https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom 25. DKG. S3-Leitlinie Prostatakarzinom, Langversion 6.2.2021. Oct. 26. EAU. Uroweb - European Association of Urology. EAU guidelines on prostate cancer - Uroweb. Available from: 2023. https://uroweb.org/guidelines/prostate-cancer 27. Nccn NCCN. NCCN guidelines prostate cancer. 2023. Available from: https://www.nccn.org/guidelines/guidelines-detail 28. MD Für eine gute und gerechte Gesundheitsversorgung 2022 MD. Für eine gute und gerechte Gesundheitsversorgung. 2022 Apr. 29. KBV. Vergütung der PSMA-PET zur Indikationsstellung einer Therapie mit Pluvicto® geregelt [Internet]. Kassenärztliche Bundesvereinigung (KBV). 2023. Available from: https://www.kbv.de/html/1150_65673.php 30. GBA. Richtlinie des Gemeinsamen Bundesausschusses über die ambulante spezialfachärztliche Versorgung ALT [Internet]. 2023 Mar. Available from: https://www.g-ba.de/downloads/62-492-3245/ASV-RL_2023-03-16_iK_2023-09-19.pdf 31. DKG. S3-Leitlinie Prostatakarzinom. Langversion. 2024, May;7 32. Blum K Offermanns M Anspruch und Realität von Budgetverhandlungen zur Umsetzung medizintechnischer Innovationen Gutachten des Deutschen Krankenhausinstituts (DKI) im Auftrag des Bundesverbandes Medizintechnologie (BVMed) 2009 Düsseldorf Blum K, Offermanns M. Anspruch und Realität von Budgetverhandlungen zur Umsetzung medizintechnischer Innovationen Gutachten des Deutschen Krankenhausinstituts (DKI) im Auftrag des Bundesverbandes Medizintechnologie (BVMed). Düsseldorf; 2009 Nov. 33. Field RI Why is health care regulation so complex? P T 2008 33 10 607 08 19750043 PMC2730786 Field RI. Why is health care regulation so complex? P T. 2008, Oct;33(10):607–08. 19750043 PMC2730786 34. Ansmann L Pfaff H Providers and patients caught between standardization and individualization: individualized standardization as a solution Int J Health Policy Manag 2017 7 4 349 52 10.15171/ijhpm.2017.95 PMC5949226 29626403 Ansmann L, Pfaff H. Providers and patients caught between standardization and individualization: individualized standardization as a solution. Int J Health Policy Manag. 2017, Aug, 12;7(4):349–52. 10.15171/ijhpm.2017.95 PMC5949226 29626403 35. Baes S, Horlai M, Leys M, Dhaene S. Physicians’ attitudes and perspectives regarding the uptake of psychosocial aspects and/or patient preferences during multidisciplinary team meetings in oncology-2020. 2020 [Internet]. Available from: https://journals.sagepub.com/doi/abs/10.1177/2053434520959678 36. Gruber C. Realisierung der lokoregionären Tumorkonferenzempfehlungen im Versorgungsalltag von Mammakarzinom-Patientinnen des Brustzentrums der Charité Berlin [Internet]. 2012 Feb. Available from: https://refubium.fu-berlin.de/bitstream/handle/fub188/12848/DissOnline-Pdf.pdf;jsessionid=9EC159928A1A94F2D92A9F1524D5CB45?sequence=1 37. Hermes-Moll K Dengler R Riese C Baumann W Tumor boards from the perspective of ambulant oncological care Oncol Res Treat 2016 39 6 377 83 10.1159/000446311 27260517 Hermes-Moll K, Dengler R, Riese C, Baumann W. Tumor boards from the perspective of ambulant oncological care. Oncol Res Treat. 2016;39(6):377–83. 27260517 10.1159/000446311 38. WINHO. Multidisziplinäre Tumorkonferenzen: Strukturen, Prozesse und Anforderungen aus Sicht der Ärztinnen und Ärzte [Internet]. Wissenschaftliches Institut der Niedergelassenen Hämatologen und Onkologen - WINHO - GmbH. 2023 Dec. Available from: https://www.zi.de/fileadmin/Downloads/Service/Forschungsfoerderung/2020/Heidt_WINHO.pdf 39. Basta YL Bolle S Fockens P Tytgat KMAJ The value of multidisciplinary team meetings for patients with gastrointestinal malignancies: A systematic review Ann Surg Oncol 2017 24 9 2669 78 10.1245/s10434-017-5833-3 28337661 PMC5539280 Basta YL, Bolle S, Fockens P, Tytgat KMAJ. The value of multidisciplinary team meetings for patients with gastrointestinal malignancies: a systematic review. Ann Surg Oncol. 2017, Sep;24(9):2669–78. 28337661 10.1245/s10434-017-5833-3 PMC5539280 40. Hollunder S Herrlinger U Zipfel M Schmolders J Janzen V Thiesler T Cross-sectional increase of adherence to multidisciplinary tumor board decisions BMC Cancer 2018 18 1 936 10.1186/s12885-018-4841-4 30268109 PMC6162965 Hollunder S, Herrlinger U, Zipfel M, Schmolders J, Janzen V, Thiesler T, et al. Cross-sectional increase of adherence to multidisciplinary tumor board decisions. BMC Cancer. 2018, Sep, 29;18(1):936. 30268109 10.1186/s12885-018-4841-4 PMC6162965 41. Lamb BW Taylor C Lamb JN Strickland SL Vincent C Green JSA Facilitators and barriers to teamworking and patient centeredness in multidisciplinary cancer teams: findings of a national study Ann Surg Oncol 2013 20 5 1408 16 10.1245/s10434-012-2676-9 23086306 Lamb BW, Taylor C, Lamb JN, Strickland SL, Vincent C, Green JSA, et al. Facilitators and barriers to teamworking and patient centeredness in multidisciplinary cancer teams: findings of a national study. Ann Surg Oncol. 2013, May, 1;20(5):1408–16. 23086306 10.1245/s10434-012-2676-9 42. Soukup T Lamb BW Arora S Darzi A Sevdalis N Green JS Successful strategies in implementing a multidisciplinary team working in the care of patients with cancer: an overview and synthesis of the available literature J Multidiscip healthc 2018 11 49 61 10.2147/JMDH.S117945 29403284 PMC5783021 Soukup T, Lamb BW, Arora S, Darzi A, Sevdalis N, Green JS. Successful strategies in implementing a multidisciplinary team working in the care of patients with cancer: an overview and synthesis of the available literature. J Multidiscip healthc. 2018, Dec, 31;11:49–61. 29403284 10.2147/JMDH.S117945 PMC5783021 43. Soukup T Sevdalis N Green JSA Lamb BW Chapman C Skolarus TA Making tumor boards more patient-centered: let’s start with the name JCO Oncol Pract 2021 17 10 591 93 10.1200/OP.20.00588 33734827 Soukup T, Sevdalis N, Green JSA, Lamb BW, Chapman C, Skolarus TA. Making tumor boards more patient-centered: let’s start with the name. JCO Oncol Pract. 2021, Oct;17(10):591–93. 33734827 10.1200/OP.20.00588 44. Abendhardt W. Qualitätssicherung: Tumorboards - Bessere Kooperation erforderlich. Deutsches Ärzteblatt [Internet]. 2012, Aug, 6;109(31–32). Available from: https://www.aerzteblatt.de/archiv/128317/Qualitaetssicherung-Tumorboards-Bessere-Kooperation-erforderlich 45. Klein R, Nutzen HM. Mehraufwand und Finanzierung von Onkologischen Spitzenzentren, Onkologischen Zentren und Organkrebszentren [Internet]. Deutsche Krebshilfe, Deutsche Krebsgesellschaft; 2017 Jan. Available from: https://www.krebshilfe.de/fileadmin/Downloads/PDFs/Stellungnahmen/Prognos_Endbericht_Deutsche_Krebshilfe.pdf 46. Hong NJL Wright FC Gagliardi AR Paszat LF Examining the potential relationship between multidisciplinary cancer care and patient survival: an international literature review J Surg Oncol 2010 102 2 125 34 10.1002/jso.21589 20648582 Hong NJL, Wright FC, Gagliardi AR, Paszat LF. Examining the potential relationship between multidisciplinary cancer care and patient survival: an international literature review. J Surg Oncol. 2010, Aug, 1;102(2):125–34. 20648582 10.1002/jso.21589 47. Kee F Owen T Leathem R Decision making in a multidisciplinary cancer team: does team discussion result in better quality decisions? Med Decis Mak 2004 24 6 602 13 10.1177/0272989X04271047 15534341 Kee F, Owen T, Leathem R. Decision making in a multidisciplinary cancer team: does team discussion result in better quality decisions? Med Decis Mak. 2004;24(6):602–13. 10.1177/0272989X04271047 15534341 48. Kesson E, George A, Burns H, Morrison D. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women|the BMJ [Internet]. 2012. Available from: https://www.bmj.com/content/344/bmj.e2718 10.1136/bmj.e2718 PMC3339875 22539013 49. Pillay B Wootten AC Crowe H Corcoran N Tran B Bowden P The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature Cancer Treat Rev 2016 42 56 72 10.1016/j.ctrv.2015.11.007 26643552 Pillay B, Wootten AC, Crowe H, Corcoran N, Tran B, Bowden P, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature. Cancer Treat Rev. 2016, Jan;42:56–72. 26643552 10.1016/j.ctrv.2015.11.007 50. Specchia ML Frisicale EM Carini E Di Pilla A Cappa D Barbara A The impact of tumor board on cancer care: evidence from an umbrella review BMC Health Serv Res 2020 20 1 73 10.1186/s12913-020-4930-3 32005232 PMC6995197 Specchia ML, Frisicale EM, Carini E, Di Pilla A, Cappa D, Barbara A, et al. The impact of tumor board on cancer care: evidence from an umbrella review. BMC Health Serv Res. 2020, Jan, 31;20(1):73. 32005232 10.1186/s12913-020-4930-3 PMC6995197 51. Keating NL Landrum MB Lamont EB Bozeman SR Shulman LN McNeil BJ Tumor boards and the quality of cancer care J Natl Cancer Inst 2013 105 2 113 21 10.1093/jnci/djs502 23274388 PMC4481638 Keating NL, Landrum MB, Lamont EB, Bozeman SR, Shulman LN, McNeil BJ. Tumor boards and the quality of cancer care. J Natl Cancer Inst. 2013, Jan, 16;105(2):113–21. 23274388 10.1093/jnci/djs502 PMC4481638 52. Hermes-Moll K, Baumann W, Kowalski C, Ohlmeier C, Gothe H, Deutschland. Mvf HVMT. 2021, Oct;4(14(05/2021)):57–61. 53. Bate J Wingrove J Donkin A Taylor R Whelan J Patient perspectives on a national multidisciplinary team meeting for a rare cancer Eur J Cancer Care (engl) 2019 28 2 e12971 30507003 10.1111/ecc.12971 Bate J, Wingrove J, Donkin A, Taylor R, Whelan J. Patient perspectives on a national multidisciplinary team meeting for a rare cancer. Eur J Cancer Care (Engl). 2019, Mar;28(2):e12971. 30507003 10.1111/ecc.12971 54. Hahlweg P Hoffmann J Härter M Frosch DL Elwyn G Scholl I Absentia: an Explor Study of How Patients are Consid in Multidiscip Cancer Team Meetings. PLoS One 2015 10 10 e0139921 10.1371/journal.pone.0139921 PMC4595280 26441328 Hahlweg P, Hoffmann J, Härter M, Frosch DL, Elwyn G, Scholl I. Absentia: an explor study of how patients are consid in multidiscip cancer team meetings. PLoS One. 2015, Oct, 6;10(10):e0139921. 10.1371/journal.pone.0139921 PMC4595280 26441328 55. Heuser C, Diekmann A, Schellenberger B, Bohmeier B, Kuhn W, Karbach U, et al. Patient participation in multidisciplinary tumor conferences from the providers’ perspective: is it feasible in routine cancer care? J Multidiscip Healthc. 2020 Nov 27: 1729–39, 13. 10.2147/JMDH.S283166 PMC7708776 33273821 56. Knötgen G Onkologische Pflege im Tumorboard Onkologe (Berl) 2020 26 11 991 97 10.1007/s00761-020-00836-0 32994670 PMC7517068 Knötgen G. Onkologische Pflege im Tumorboard. Onkologe (Berl). 2020;26(11):991–97. 32994670 10.1007/s00761-020-00836-0 PMC7517068 57. Fleissig A Jenkins V Catt S Fallowfield L Multidisciplinary teams in cancer care: are they effective in the UK? The Lancet Oncol 2006 7 11 935 43 10.1016/S1470-2045(06)70940-8 17081919 Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer care: are they effective in the UK? The Lancet Oncol. 2006, Nov;7(11):935–43. 17081919 10.1016/S1470-2045(06)70940-8 58. NHS. National cancer peer review programme report 2010/2011 [Internet]. 2011 Nov. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/216205/dh_131669.pdf 59. Taylor C Munro AJ Glynne-Jones R Griffith C Trevatt P Richards M Multidisciplinary team working in cancer: what is the evidence? BMJ 2010 340 c951 10.1136/bmj.c951 20332315 Taylor C, Munro AJ, Glynne-Jones R, Griffith C, Trevatt P, Richards M, et al. Multidisciplinary team working in cancer: what is the evidence? BMJ. 2010, Mar, 23;340:c951. 20332315 10.1136/bmj.c951 60. Schmalenberg H Schmalenberg H Hartmann R Baumann W Interdisziplinäres Qualitätsmanagement und Zentrumsbildung in der Onkologie Qualitätsmanagement und Zertifizierung in der Onkologie [Internet] 2010 Berlin, Heidelberg Springer 107 41 Schmalenberg H. Interdisziplinäres Qualitätsmanagement und Zentrumsbildung in der Onkologie. In: Schmalenberg H, Hartmann R, Baumann W, editors. Qualitätsmanagement und Zertifizierung in der Onkologie [Internet]. Berlin, Heidelberg: Springer; 2010. p. 107–41. Available from: 10.1007/978-3-642-12840-0_6. [cited 2023 Jul 24]. 61. Dengler R Straub N Bredow L Becker J Hornschuch M Riedel O Outpatient medical specialist care (ASV): a multiperspective study on status quo, challenges and perspectives ZEFQ 2022 174 70 81 10.1016/j.zefq.2022.06.003 36097002 Dengler R, Straub N, Bredow L, Becker J, Hornschuch M, Riedel O, et al. Outpatient medical specialist care (ASV): a multiperspective study on status quo, challenges and perspectives. ZEFQ. 2022, Nov, 1;174:70–81. 10.1016/j.zefq.2022.06.003 36097002 62. IGES Institute. Wissenschaftliche Evaluation des Produktivbetriebs der Anwendungen der Telematikinfrastruktur 2022 [Internet]. 2023. Available from: https://www.gematik.de/media/gematik/Medien/Telematikinfrastruktur/TI-Atlas/IGES-Studie_Wissenschaftliche_Evaluation_des_Produktivbetriebs_der_Anwendungen_der_TI_2022.pdf 63. Lievens Y Borras JM Grau C Provision and use of radiotherapy in Europe Mol Oncol 2020 14 7 1461 69 10.1002/1878-0261.12690 32293084 PMC7332207 Lievens Y, Borras JM, Grau C. Provision and use of radiotherapy in Europe. Mol Oncol. 2020;14(7):1461–69. 32293084 10.1002/1878-0261.12690 PMC7332207 64. Wright SJ Newman WG Payne K Accounting for capacity constraints in economic evaluations of precision medicine: a systematic review Pharmacoeconomics 2019 37 8 1011 27 10.1007/s40273-019-00801-9 31087278 PMC6597608 Wright SJ, Newman WG, Payne K. Accounting for capacity constraints in economic evaluations of precision medicine: a systematic review. Pharmacoeconomics. 2019;37(8):1011–27. 31087278 10.1007/s40273-019-00801-9 PMC6597608 65. ACS. Optimal resources for breast care 2024 standards [Internet]. 2023 Feb. Available from: https://accreditation.facs.org/accreditationdocuments/NAPBC/Standards/Optimal_Resources_for_Breast_Care_2024.pdf 66. Dobbs RW Stinson J Vasavada SR Caldwell BM Freeman VL Garvey DF Helping men find their way: improving prostate cancer clinic attendance via patient navigation J Community Health 2020 45 3 561 68 10.1007/s10900-019-00776-w 31713018 Dobbs RW, Stinson J, Vasavada SR, Caldwell BM, Freeman VL, Garvey DF, et al. Helping men find their way: improving prostate cancer clinic attendance via patient navigation. J Community Health. 2020, Jun, 1;45(3):561–68. 31713018 10.1007/s10900-019-00776-w 67. Freund KM Battaglia TA Calhoun E Darnell JS Dudley DJ Fiscella K Impact of patient navigation on timely cancer care: the patient navigation research program J Natl Cancer Inst 2014 106 6 dju115 10.1093/jnci/dju115 24938303 PMC4072900 Freund KM, Battaglia TA, Calhoun E, Darnell JS, Dudley DJ, Fiscella K, et al. Impact of patient navigation on timely cancer care: the patient navigation research program. J Natl Cancer Inst. 2014, Jun, 14;106(6):dju115. 24938303 10.1093/jnci/dju115 PMC4072900 68. Albalooshi B M A Bagheri F Miyanath S Ray B Muhasin M Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer Asia Ocean J Nucl Med Biol 2020 8 1 1 7 32064277 10.22038/aojnmb.2019.43943.1293 PMC6994779 Albalooshi B, M A, Bagheri F, Miyanath S, Ray B, Muhasin M, et al. Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer. Asia Ocean J Nucl Med Biol. 2020;8(1):1–7. 32064277 10.22038/aojnmb.2019.43943.1293 PMC6994779 69. Hricak H Ward ZJ Atun R Abdel-Wahab M Muellner A Scott AM Increasing access to imaging for addressing the global cancer epidemic Radiology 2021 301 3 543 46 10.1148/radiol.2021211351 34581630 PMC8630531 Hricak H, Ward ZJ, Atun R, Abdel-Wahab M, Muellner A, Scott AM. Increasing access to imaging for addressing the global cancer epidemic. Radiology. 2021, Sep, 28;301(3):543–46. 34581630 10.1148/radiol.2021211351 PMC8630531 70. Robu S Schottelius M Eiber M Maurer T Gschwend J Schwaiger M Preclinical evaluation and first patient application of 99mTc-PSMA-I & amp;S for SPECT imaging and radioguided surgery in prostate cancer J Nucl Med 2017 58 2 235 42 10.2967/jnumed.116.178939 27635024 Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, et al. Preclinical evaluation and first patient application of 99mTc-PSMA-I & amp;S for SPECT imaging and radioguided surgery in prostate cancer. J Nucl Med. 2017, Feb;58(2):235–42. 27635024 10.2967/jnumed.116.178939 71. Bergen N Labonté R “Everything Is Perfect, and We Have No Problems”: detecting and limiting social desirability bias in qualitative research Qual Health Res 2020 30 5 783 92 10.1177/1049732319889354 31830860 Bergen N, Labonté R. “Everything Is Perfect, and We Have No Problems”: detecting and limiting social desirability bias in qualitative research. Qual Health Res. 2020, Apr, 1;30(5):783–92. 31830860 10.1177/1049732319889354 72. Larson RB Controlling social desirability bias Int J Market Res 2019 61 5 534 47 10.1177/1470785318805305 Larson RB. Controlling social desirability bias. Int J Market Res. 2019, Sep, 1;61(5):534–47. ",
  "metadata": {
    "Title of this paper": "Controlling social desirability bias",
    "Journal it was published in:": "BMC Health Services Research",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490126/"
  }
}